Keryx Biopharmaceuticals, Inc. has received $-0.27 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 5 Financial Advisor in the Stock Trading Firms. Among 5 Analysts, Bottom line EPS Estimate for the current quarter is $-0.32 while the top line estimate is $-0.21 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 26.11%.
Keryx Biopharmaceuticals, Inc. results fell short with a surprise EPS of -77.27% or $-0.17. The Actual EPS was $-0.39 compared to the Estimated EPS of $-0.22 during its most recent quarterly earnings.
In the last quarter, Keryx Biopharmaceuticals, Inc. reported Annual Earnings of $-0.39. Based on the filings, last years Annual Earnings was, $-1.19. In the last Quarter, KERX reported a surprise Earnings per Share of -77.27% . The consensus estimate for current quarter is $-0.27 and for the current fiscal year, the estimate is $-1.47. For the Next fiscal year, the estimate is $-0.62 based on the consensus.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) : On Tuesday heightened volatility was witnessed in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) which led to swings in the share price. The stock opened for trading at $4.66 and hit $5.05 on the upside , eventually ending the session at $4.99, with a gain of 8.71% or 0.4 points. The heightened volatility saw the trading volume jump to 2,268,647 shares. The 52-week high of the share price is $7.8 and the company has a market cap of $529 million. The 52-week low of the share price is at $3.11 .
Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.